Compare Kokoh Inti Arebama Tbk (KOIN) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kokoh Inti Arebama Tbk vs Organon Pharma Indonesia Tbk. — how do they compare? Kokoh Inti Arebama Tbk trades at Rp78 (market cap 78.47B, 61.5K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Organon Pharma Indonesia Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.
| KOIN | SCPI | |
|---|---|---|
Market Cap | 78.47B | 104.4B |
Volume | 61.5K | — |
Lot | 615 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kokoh Inti Arebama Tbk
PT Kokoh Inti Arebama Tbk (the company) was established on 6 Jul 2001 based on Notaries Deed No. 27. The Company’s articles of association has been amended several times, most recently by notarial deed No. 7 of Mr. Nanda Fauz Iwan, SH., dated Aug 30, 2007, concerning among others, the change board commission and Company’s capital structure. PT Kokoh Inti Arebama is an Indonesia-based distributor. The Company is engaged in the distribution of ceramic wall, floor and roof tiles under the brands Lacassa, KIA and Impresso. The Company also acts as a distributor for sanitary products under the brand Claytan, paint products under the brand Kansai Paint and cement products under the brand Jaya Mortar. The Company has one subsidiary namely PT Karya Makmur Kreasi Prima. Headquartered in Jakarta, Indonesia, the Company has 16 branch offices and two stock points.
Read more on KOIN →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
